ArriVent BioPharma FY23 EPS $(32.38) Vs $(28.90) YoY
ArriVent BioPharma FY23 EPS $(32.38) Vs $(28.90) YoY
ArriVent BioPharma 23财年每股收益为32.38美元，同比增长28.90美元
Fiscal Year 2023 Financial Results
2023 财年财务业绩
- Research and development expenses were $64.9 million and $30.4 million for the years ended December 31, 2023 and 2022, respectively. The increase in expense was primarily due to increased clinical spending on trials related to furmonertinib.
- General and administrative expenses were $9.7 million and $6.5 million for the years ended December 31, 2023 and 2022, respectively. The increase was primarily due to increased external costs related to preparing for and operating as a public company, as well as increased personnel costs to support these activities.
- Net loss was $69.3 million and $37.0 million for the years ended December 31, 2023 and 2022, respectively.
- As of December 31, 2023, the company had cash, cash equivalents and marketable securities of $150.4 million, which, with the proceeds from our IPO in January 2024, is expected to fund operations into 2026.
- As of December 31, 2023, the company had cash, cash equivalents and marketable securities of $150.4 million, which, with the proceeds from our IPO in January 2024, is expected to fund operations into 2026.
- 截至2023年12月31日和2022年12月31日止年度的研发费用分别为6,490万美元和3,040万美元。支出的增加主要是由于与弗莫那替尼相关的试验的临床支出增加。
- 截至2023年12月31日和2022年12月31日止年度，一般和管理费用分别为970万美元和650万美元。增长的主要原因是与上市公司筹备和运营相关的外部成本增加，以及支持这些活动的人事成本增加。
- 截至2023年12月31日和2022年12月31日止年度的净亏损分别为6,930万美元和3,700万美元。
- 截至2023年12月31日，该公司的现金、现金等价物和有价证券为1.504亿美元，加上我们在2024年1月首次公开募股的收益，预计将为2026年的运营提供资金。
- 截至2023年12月31日，该公司的现金、现金等价物和有价证券为1.504亿美元，加上我们在2024年1月首次公开募股的收益，预计将为2026年的运营提供资金。